Evotec (NASDAQ:EVO) Sees Unusually-High Trading Volume

Evotec SE (NASDAQ:EVO) saw strong trading volume on Wednesday . 29,376 shares changed hands during mid-day trading, a decline of 74% from the previous session’s volume of 111,641 shares.The stock last traded at $5.25 and had previously closed at $5.12.

Analyst Ratings Changes

EVO has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Evotec in a report on Thursday, May 23rd.

Evotec Stock Performance

The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $4.92 and a two-hundred day moving average price of $6.85.

Institutional Trading of Evotec

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quadrant Capital Group LLC acquired a new stake in Evotec in the 4th quarter valued at approximately $25,000. Cetera Advisors LLC acquired a new stake in Evotec in the 1st quarter valued at approximately $188,000. Optiver Holding B.V. increased its position in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the period. Finally, Mubadala Investment Co PJSC acquired a new stake in Evotec in the 4th quarter valued at approximately $53,931,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.